ImmuneOnco Biopharmaceuticals (HKG:1541) said Chairman and Chief Executive Tian Wenzhi purchased 50,000 H shares on Dec. 3 at an average price of HK$6.6258, according to a Wednesday Hong Kong bourse filing.
Shares of the firm were up over 3% in Thursday morning trade.
The purchase lifted Tian's stake to over 116.1 million shares, or 26.91% of the company's issued capital.